Genotek genotec

Genotek is an international company founded in Russia in 2010 by Artem Elmuratov, Valery Ilyinsky and Kirill Petrenko. The company's offices are located in, Russia, and Kazakhstan USA. Cyprus More than 2.5 million dollars representatives of RuStarsVentures, the agricultural holding "," Rusagro as well as a number of private investors invested in Genotek.

Services

The laboratory of the Genetico Center is registered in the information and analytical system of the Russian Science Foundation (RNF) as a world-class infrastructure facility. The Center also received accreditation from the Skolkovo Foundation as a Collective Use Center (CCP). Genetico provides genome sequencing (NGS) services to Biomedical Cluster residents, single cell analysis and their specific activity, chromosomal micromatric analysis, and conducts genetic mutation search and bioinformatic studies.

The Genetico laboratories are equipped with the latest generation of sequencers and robotic equipment and enable advanced genetic research required for medicine, genomics and proteomics.

Genotek has one of the largest genetic laboratories in Eastern Europe, in which it performs research for private clients of clients and medical clinics from 71 countries of the world. The entire analysis process and data storage are localized in Russia. Genotek's clients include Russia's largest medical institutions, including the Russian Cancer Research Center, the Russian Children's Clinical Hospital, the First Moscow State Medical University and others. Cooperation with clinics allows you to clarify diagnoses, select effective treatment and save people's lives.

2024: Purchase of the telemedicine division of Yandex

Yandex sold a telemedicine line operating under the Yandex Health brand. This became known on September 16, 2024. The new owner is Genotek, a company specializing in genetic research and personalized medicine. Read more here.

2020

Raising $4 million in investments, including from Yandex

In December 2020, it became known that Genotek attracted a round of investments of $4 million. The leading and new investor in the round was Yandex. The representative of Yandex will join the board of directors of Genotek. The founders of the company Artem Elmuratov and Ilyinsky Valery retained control.

Like other Genotek shareholders, Yandex will not have access to the company's technology solutions and user data. There is no plan to change the privacy policy, which implies a complete ban on the transfer of any personal data of customers to anyone, including shareholders of the company. Data on the exact share and who will join the board has not been made public.

The Russian Medical and Genetic Center Genotek raised $4 million. Among investors - Yandex

The investments received will be aimed at creating new more affordable products and developing services that will enable the use of genetic test results in many life situations, including personalized recommendations for disease treatment, health insurance, nutrition and family history studies. The funds will also go to the development of the scientific, medical and commercial base of the company, its representative explained in a conversation with TAdviser.

Our teams are already working closely on delivery issues, on data processing algorithms and in automating communication with customers. We see joint interest in other areas - the development of telemedicine services, education, - said the founder of the startup Valery Ilyinsky, commenting on the deal.

According to SPARK-Interfax, by December 24, 2020, Ilyinsky owns 80% in Genotek LLC, another 20% in Genotek Holding LLC. This company, in turn, is owned by the Cypriot Cleome Holdings ltd.

For Genotek, this is the third round of investments, and for Yandex, this is the first project in the field of genetic research. According to Elena Bunina, CEO of Yandex in Russia, the field of medical genetics is just beginning to develop, and Genotek, in her opinion, has great growth potential. At the same time, the company is already developing a project in the field of medicine in general - it owns the Yandex.Health telemedicine service.

Co-founder of the Atlas biomedical holding Sergei Musienko, in a conversation with Vedomosti, highly appreciated the growth potential of both the Russian genetic research market and the world one. According to him, only the consumer segment of this industry, which involves research for private clients without a doctor's appointment (tests on predispositions, genealogy), is growing annually in Russia by about 50%. Such an indicator is due to the fact that the niche itself is new and develops only at the expense of local players, says Musienko. At the same time, he states that the Russian market for genetic research is less than 1% of the world, since, according to him, in other countries this industry is much better developed^[1]

Production of highly sensitive PCR tests

In early 2020, the company developed and launched the production of highly sensitive PCR tests for diagnosing a new one, coronavirus infections which are supplied to laboratories Russia and CIS countries. Genotek has become a member COVID-19 of the Host Genetics international consortium, which aims to identify genetic factors for resistance to the new coronavirus infection.

2017: Investments from Pharmstandard

At the beginning of 2017, Pharmstandard contributed a million dollars of investment capital to the Genotek Medical and Genetic Center, and Viktor Kharitonin replenished the composition of the directors.

Investment capital is intended to develop the direction of research in the genetic and pharmaceutical industries. Genotek's plans are ambitious - the development of molecular genetic diagnostics technologies, as well as therapeutic intervention using personalized drugs that the company intends to launch into production.

"The partnership" Genotek "and" Pharmstandard "will be aimed at creating a full cycle in the field of medicine: from the development and production of drugs to personalized approaches in therapy," said the general director and co-founder of Genotek "Ilyinsky Valery.

Pharmstandard representatives believe that investing in this industry will bring great benefits, since the pharmaceutical sector in Russia is now at an initial stage of development: the market volume is only 100 million rubles a year. On the global level, the markets for genetic analyses and diagnostics and personalized medicine are among the fast-growing segments of the economy.

2010: Founding of the Company

Genotek was founded in 2010 by graduates of Moscow State University. M.V. Lomonosov Valery Ilyinsky, Artem Elmuratov and Kirill Petrenko. The data of DNA studies carried out by the company make it possible to identify the likelihood of diseases, determine the origin, find relatives, develop a personal training and nutrition program with the doctor, as well as diagnose and choose an effective therapy.

Notes